Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9662315 | PURPLE BIOTECH | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
May, 2029
(5 years from now) | |
US9408837 | PURPLE BIOTECH | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
Feb, 2030
(6 years from now) | |
US10925835 | PURPLE BIOTECH | Celecoxib and amlodipine formulation and method of making the same |
Jun, 2038
(15 years from now) | |
US10945960 | PURPLE BIOTECH | Celecoxib and amlodipine formulation and method of making the same |
Jun, 2038
(15 years from now) | |
US10350171 | PURPLE BIOTECH | Celecoxib and amlodipine formulation and method of making the same |
Jun, 2038
(15 years from now) |
Market Authorisation Date: 31 May, 2018
Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate
Dosage: TABLET;ORAL
15
United States
1
China
1
Israel
1
Canada
1
Mexico
1
Japan
1
Australia
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic